Phase II Trial of Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer (With Trastuzumab in HER2 Positive Patients).
Latest Information Update: 25 Nov 2021
Price :
$35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Adverse reactions
- 02 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 May 2011 Actual end date (September 2010) added as reported by ClinicalTrials.gov.
- 14 Oct 2008 Status changed from recruiting to active, no longer recruiting.